InsidersTradesSigma
Follow the 拓新药业 share price and the full management transaction log of the company, a listed equity based in China. Shares are listed on the CN market, under the oversight of SSE / SZSE (CSRC). Operating in the Health Care sector, 拓新药业 has logged 10 reports. Market capitalisation: €2.8bn. The latest transaction was filed on 23 February 2023 (Sale). Among the most active insiders: 蔡玉瑛. Every trade is accessible without an account.
10
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€9m
10 ops.
Sell Volume
7Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,975 of 28,753 companies
25.1
score / 100
Value28
Quality23
FCF yld-2.5%
Earn yld-2.5%
EV/EBITDA·
ROE-5.1%
Gross mgn26%
Net mgn-18%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 23 February 2023
Declarations10 total
10 of 10 declarations
About 拓新药业
拓新药业 is a company in the health and pharmaceutical sector, listed on the XSHE market. It focuses on the development and commercialization of innovative drugs.